<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">20150644</PMID>
        <DateCreated>
            <Year>2010</Year>
            <Month>02</Month>
            <Day>12</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2010</Year>
            <Month>03</Month>
            <Day>17</Day>
        </DateCompleted>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1791-7530</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>30</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2010</Year>
                        <Month>Jan</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Anticancer research</Title>
                <ISOAbbreviation>Anticancer Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Evaluation of the prognostic value of CD44 in glioblastoma multiforme.</ArticleTitle>
            <Pagination>
                <MedlinePgn>253-9</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="BACKGROUND/AIM" NlmCategory="OBJECTIVE">Glioblastoma and astrocytoma are the most common brain tumors affecting adults 45-60 years of age. The poor prognosis for glioblastoma patients results from recurrence after treatment. There is therefore an urgent need to develop diagnostic and prognostic markers as well as new therapies.</AbstractText>
                <AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">Microarray analyses of clinical specimens from glioblastoma patients were used to identify potential tumor markers. Expression of candidate genes was analyzed by real-time reverse transcription-polymerase chain reaction and by immunoblotting and immunohistochemistry.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Five potential markers (CD44 antigen (CD44), growth arrest and DNA-damage-inducible, alpha (GADD45A), fibronectin 1 (FN1), CD63 antigen (CD63) and secreted phosphoprotein 1 (SPP1)) showed expression patterns that correlated significantly with malignant glioma. In particular, expression of the CD44 antigen was elevated in more severe tumor types, and higher in tumor cores than in peripheral regions. However, lower levels of CD44 expression surprisingly correlated with lower survival.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The CD44 antigen is a promising candidate for further development as a prognostic and therapeutic tool.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Wei</LastName>
                    <ForeName>Kuo-Chen</ForeName>
                    <Initials>KC</Initials>
                    <Affiliation>Chang Gung Memorial Hospital, Chang Gung University College of Medicine, No. 5, Fu Shin Street, Kweishan, Taoyuan, Taiwan, R.O.C. kuochenwei@adm.cgmh.org.tw</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Huang</LastName>
                    <ForeName>Chiung-Yin</ForeName>
                    <Initials>CY</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Pin-Yuan</ForeName>
                    <Initials>PY</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Feng</LastName>
                    <ForeName>Li-Ying</ForeName>
                    <Initials>LY</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wu</LastName>
                    <ForeName>Tai-Wei Erich</ForeName>
                    <Initials>TW</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Shu-Mei</ForeName>
                    <Initials>SM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tsai</LastName>
                    <ForeName>Hong-Chieh</ForeName>
                    <Initials>HC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lu</LastName>
                    <ForeName>Yu-Jen</ForeName>
                    <Initials>YJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tsang</LastName>
                    <ForeName>Ngan-Ming</ForeName>
                    <Initials>NM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tseng</LastName>
                    <ForeName>Chen-Kan</ForeName>
                    <Initials>CK</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pai</LastName>
                    <ForeName>Ping-Ching</ForeName>
                    <Initials>PC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shin</LastName>
                    <ForeName>Jyh-Wei</ForeName>
                    <Initials>JW</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Evaluation Studies</PublicationType>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Greece</Country>
            <MedlineTA>Anticancer Res</MedlineTA>
            <NlmUniqueID>8102988</NlmUniqueID>
            <ISSNLinking>0250-7005</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Antigens, CD44</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>CD44 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Tumor Markers, Biological</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Antigens, CD44</DescriptorName>
                <QualifierName MajorTopicYN="N">biosynthesis</QualifierName>
                <QualifierName MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Brain Neoplasms</DescriptorName>
                <QualifierName MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Glioblastoma</DescriptorName>
                <QualifierName MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Immunohistochemistry</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Oligonucleotide Array Sequence Analysis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Prognosis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Tumor Markers, Biological</DescriptorName>
                <QualifierName MajorTopicYN="N">biosynthesis</QualifierName>
                <QualifierName MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2010</Year>
                <Month>2</Month>
                <Day>13</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2010</Year>
                <Month>2</Month>
                <Day>13</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2010</Year>
                <Month>3</Month>
                <Day>18</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">30/1/253</ArticleId>
            <ArticleId IdType="pubmed">20150644</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
